Nektar Therapeutics (NKTR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$74.19-2.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NKTR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -32.3% |
| Our one-year growth estimate | diamond | 3.3% |
Growth built into the price is above our model estimate.
The price assumes 35.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
NKTR — CFO transition
Dated 2026-05-08
interim Chief Financial Officer — Sandra Gardiner: Sandra Gardiner is retiring and stepping down as interim Chief Financial Officer, with Linda Rubinstein succeeding her in the same role.
Why it matters: A strong cash position helps with clinical trials and operations. It shows financial health.
Supportive ifCash and investments increase from $1,023.4 million as of June 30, 2026.
Worry ifCash and investments decrease significantly or fail to grow in the next quarter.
Why it matters: This meeting is key for the Phase 3 program for alopecia areata. Good results could build trust in rezpegaldesleukin.
Supportive ifA press release detailing a successful outcome from the End-of-Phase 2 meeting with the FDA.
Worry ifAn announcement will show there are still issues or concerns from the End-of-Phase 2 meeting.
Why it matters: Continued earnings misses could show bigger financial problems. This may hurt investor feelings.
Worry ifAnother earnings report shows a miss greater than the previous quarter's results.
Less concerning ifEarnings report shows a surprise beat or meets expectations.
Why it matters: If the health care sector's revenue growth picks up, it could help Nektar's performance. A strong sector can lift individual stocks.
Supportive ifHealth care sector revenue growth speeds up to 10% or more.
Worry ifSector revenue growth keeps slowing down or stays under 10%.
Why it matters: These results will show how well rezpegaldesleukin works long-term for alopecia areata. Good data could help its market position.
Supportive ifThe 52-week data shows big improvements in SALT scores. This is for patients using rezpegaldesleukin.
Worry ifData shows no big improvements in SALT scores or side effects in the 52-week study.
Why it matters: The study results will show how effective the treatment is. This could change investor views on the company's future.
Supportive ifThe REZOLVE-AA study shows positive results. These results show strong treatment benefits.
Worry ifThe REZOLVE-AA study shows negative results. These results show no treatment benefits.
Why it matters: A new CFO can change financial strategy and investor confidence. This transition may affect stock performance.
Watch forThe market reacted well after Linda Rubinstein became CFO. Financial performance stayed stable.
Also watch forThe market reacted poorly after the CFO change. Financial stability was hurt.
Why it matters: This data will show how well rezpegaldesleukin works for alopecia areata. Good results could help more patients.
Supportive ifThe 52-week data from the REZOLVE-AA study is expected to be presented in Q4 2026.
Worry ifThe data shows no real change in SALT scores for patients.
Why it matters: How well the stock offering does can affect the company's money. It can also change how investors feel.
Supportive ifThe stock offering was successful. There was strong demand from investors.
Worry ifThere was weak demand for the stock offering. This may lead to a smaller size or cancellation.
Why it matters: Starting this trial shows Nektar is advancing its lead drug rezpegaldesleukin. Success here could boost confidence in its pipeline.
Supportive ifThe Phase 3 ZENITH AD trials for atopic dermatitis start in July 2026.
Worry ifThe trial initiation is delayed beyond July 2026.
Why it matters: Cash updates will show financial health and ability to pay for ongoing trials. A strong cash position helps development.
Supportive ifCash and investments are over $1 billion, providing a strong base for clinical trials.
Worry ifCash position drops a lot, raising worries about funding future trials.
Why it matters: This meeting is key for the Phase 3 program for alopecia areata. Good results could raise confidence in rezpegaldesleukin.
Supportive ifNektar announces a successful outcome from the End-of-Phase 2 meeting with FDA in Q2 2026.
Worry ifThe meeting does not yield alignment on the Phase 3 program.
Why it matters: This agreement is important for raising money. A successful deal could help financial health.
Supportive ifThe underwriting agreement is done. They raised more than $150 million.
Worry ifThey failed to complete the agreement or raised less than $100 million.
Why it matters: This study is key for rezpegaldesleukin's growth. It shows progress in treating alopecia areata.
Supportive ifThe Phase 3 study in alopecia areata will start as planned in early 2027.
Worry ifThe start of the Phase 3 study in alopecia areata is delayed past early 2027.
Why it matters: Nektar's cash position affects its ability to pay for clinical trials. A strong cash position helps development.
Supportive ifCash and investments go up a lot after the $373.8 million public offering in April 2026.
Worry ifCash position drops a lot or does not support clinical trials.
Why it matters: This meeting will align Nektar on the Phase 3 program for alopecia areata. It is crucial for future development plans.
Supportive ifThe FDA agreed on the Phase 3 program for alopecia areata.
Worry ifFailure to align with FDA, leading to delays in the Phase 3 program.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$167 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $670 loss on $10,000 · 6.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,654 loss on $10,000 · 46.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.